iRadimed Corporation — Earnings Quality Grade C
IRMD · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 60 days, change +7 days YoY
AR growth 29.5% exceeds revenue growth 14.4%
Revenue grew 14.4% but CFFO declined -2.6%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
Inventory 11.7% vs COGS 15.4%. Normal
CapEx growth -4.5% vs revenue 14.4%. Normal
SG&A/Gross Profit = 54.7%. Normal
Gross margin 76.7%, change -0.2pp. Stable
Cash Flow Quality
CFFO/NI = 1.11. Profits backed by cash
FCF $0.0B, FCF/NI = 0.74
Accruals ratio = -2.3%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 4% of equity. Manageable
Leverage manageable
Other assets -32.5% vs revenue 14.4%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 9% YoY. Normal
Manipulation Score
M-Score = -2.55 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor IRMD continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25